ライフサイエンスコーパス: demyelinating disease

1 ler's murine encephalomyelitis virus-induced demyelinating disease.

2 icrocystic macular edema is not specific for demyelinating disease.

3 gression in a secondary progressive model of demyelinating disease.

4 ts the potential for cell-based treatment of demyelinating disease.

5 ovement disorders, psychiatric features, and demyelinating disease.

6 cephalitis, followed by a nonlethal, chronic demyelinating disease.

7 y chronic hemolysis and relapsing peripheral demyelinating disease.

8 lammatory and proliferative genes to promote demyelinating disease.

9 lding a comprehensive model for TMEV-induced demyelinating disease.

10 l role in the pathogenicity of virus-induced demyelinating disease.

11 ion against the development of virus-induced demyelinating disease.

12 t into the mechanisms promoting inflammatory demyelinating disease.

13 al infection, leading to the pathogenesis of demyelinating disease.

14 undermine vitamin D3-mediated inhibition of demyelinating disease.

15 nonuclear cells (PBMCs) of 228 subjects with demyelinating disease.

16 ler's murine encephalomyelitis virus-induced demyelinating disease.

17 T cell response offers protection from this demyelinating disease.

18 ENT Multiple sclerosis is a severe, chronic, demyelinating disease.

19 n of viral proteins during the late stage of demyelinating disease.

20 t to both viral persistence and TMEV-induced demyelinating disease.

21 model for studies of viral encephalitis and demyelinating disease.

22 ctive in experimental models of inflammatory demyelinating disease.

23 cells play in development and progression of demyelinating disease.

24 ult pathway in the CNS in nonimmune-mediated demyelinating disease.

25 specific CD4(+) T cell responses and reduced demyelinating disease.

26 tiate oligodendrocyte survival in autoimmune demyelinating disease.

27 the CNS which contributes to development of demyelinating disease.

28 he first confirmed antigenic target in human demyelinating disease.

29 al therapeutical avenue for lesion repair in demyelinating disease.

30 n HLA class II molecules in inflammatory and demyelinating disease.

31 ction and induce the pathogenesis of chronic demyelinating disease.

32 istance or susceptibility to virally induced demyelinating disease.

33 ple sclerosis (MS) is a human CNS autoimmune demyelinating disease.

34 d progression of the autoimmune response and demyelinating disease.

35 ation in OPCs, contributing to Th17-mediated demyelinating disease.

36 sponses and contribute to the development of demyelinating disease.

37 associated with an inflammatory white matter demyelinating disease.

38 f antiserum to IFN-beta led to a more severe demyelinating disease.

39 an affect the development and progression of demyelinating disease.

40 ogically distinct subsets of subjects with a demyelinating disease.

41 loped significantly less severe TMEV-induced demyelinating disease.

42 e of tissue injury in experimental and human demyelinating disease.

43 specific marker for a central nervous system demyelinating disease.

44 subsets of patients with different forms of demyelinating disease.

45 nent role in the development of TMEV-induced demyelinating disease.

46 t leukodystrophy (ADLD), a fatal adult onset demyelinating disease.

47 accelerating myelin clearance and improving demyelinating disease.

48 susceptibility of mice to the development of demyelinating disease.

49 a key target for enhancing myelin repair in demyelinating diseases.

50 A class II genes in chronic inflammatory and demyelinating diseases.

51 e for oligodendrogenesis and remyelinaton in demyelinating diseases.

52 PCs) offer a promising approach for treating demyelinating diseases.

53 and adhesion and has direct implications for demyelinating diseases.

54 may provide new avenues in the treatment of demyelinating diseases.

55 ual function and may be a general feature of demyelinating diseases.

56 humans, may find further therapeutic use in demyelinating diseases.

57 ole of the innate immune system in mediating demyelinating diseases.

58 esoxime could be useful for the treatment of demyelinating diseases.

59 his pool of progenitors to replace myelin in demyelinating diseases.

60 nesis of central nervous system inflammatory demyelinating diseases.

61 rovide an effective therapeutic approach for demyelinating diseases.

62 JME may shed new light on MS and other human demyelinating diseases.

63 yelination, which has broad implications for demyelinating diseases.

64 ernodal axon in paraneoplastic syndromes and demyelinating diseases.

65 c proteins in myelin with relevance to human demyelinating diseases.

66 mportant role in the pathogenesis underlying demyelinating diseases.

67 xonal degeneration that occurs in peripheral demyelinating diseases.

68 ying pathogenesis in autoimmune inflammatory demyelinating diseases.

69 e development of multiple sclerosis or other demyelinating diseases.

70 sclerosis and a composite end point of other demyelinating diseases.

71 ral nervous system inflammatory and acquired demyelinating diseases.

72 nt diagnoses of multiple sclerosis and other demyelinating diseases.

73 al relationship between qHPV vaccination and demyelinating diseases.

74 ferentiation in multiple sclerosis and other demyelinating diseases.

75 development of multiple sclerosis and other demyelinating diseases.

76 aluate their roles and clinical relevance in demyelinating diseases.

77 ent neuron-supportive programme in inherited demyelinating disease?

78 ecific CD8(+) T cells in the pathogenesis of demyelinating disease, a single amino acid substitution

79 6 transgene (IL-6 Tg) develop a TMEV-induced demyelinating disease accompanied by an increase in vira

80 r the development of Tob1 as a biomarker for demyelinating disease activity.

81 Multiple sclerosis (MS) is an autoimmune demyelinating disease and a common cause of neurological

82 ive lesions are an uncommon manifestation of demyelinating disease and can pose a diagnostic challeng

83 In multiple sclerosis (MS), an autoimmune demyelinating disease and common cause of neurodegenerat

84 r vitamin D in the regenerative component of demyelinating disease and identify a new target for remy

85 l as other leukocytes for the development of demyelinating disease and may represent a novel therapeu

86 ation abnormalities seen in association with demyelinating disease and optic neuritis, although evide

87 and other cell types for the development of demyelinating disease and suggest that expression of VCA

88 neficial both for enhancing remyelination in demyelinating diseases and for increasing neural plastic

89 the potential for enhanced remyelination in demyelinating diseases and increased neural plasticity i

90 target, as well as an imaging biomarker, for demyelinating diseases and potentially for other disease

91 hat implicate glial gap junction proteins in demyelinating diseases and the therapeutic potential of

92 our understanding of idiopathic inflammatory demyelinating diseases and their treatment.

93 red in patients with neuromyelitis optica, a demyelinating disease, and are now being used to diagnos

94 hemorrhage, intracranial hemorrhage, spine, demyelinating disease, and epileptic patients.

95 design of neuroprotective strategies for CNS demyelinating disease, and our model identifies the spik

96 hich the olfactory system is affected in CNS demyelinating diseases, and raises intriguing questions

97 ivation and the pathogenesis of TMEV-induced demyelinating disease are largely unknown.

98 CNS repair following lesions associated with demyelinating diseases are still unresolved.

99 n A59, causes acute encephalitis and chronic demyelinating disease as well as hepatitis in mice.

100 Multiple sclerosis is a demyelinating disease associated with an inflammatory im

101 irmed that NFM was not a critical Ag driving demyelinating disease because NFM18-30-specific T cells

102 d cell leukodystrophy (GLD), a genetic fatal demyelinating disease, because its rapidly progressive d

103 differential susceptibility to TMEV-induced demyelinating disease between SJL and B6 mice.

104 immune response on development of autoimmune demyelinating disease by altering the innate immune resp

105 unogenic in C57BL/6 mice but fails to induce demyelinating disease by polyclonal T cells despite havi

106 dy definitively demonstrates that autoimmune demyelinating disease can be driven by distinct Th-polar

107 ultifocal leukoencephalopathy (PML), a fatal demyelinating disease caused by JC virus (JCV) infection

108 id-cell leukodystrophy (GLD) is an inherited demyelinating disease caused by the deficiency of the ly

109 al leukoencephalopathy (PML) is a lethal CNS demyelinating disease caused by the human neurotropic po

110 Multiple sclerosis (MS) is a human demyelinating disease characterized by multifocal region

111 Because functional restoration in demyelinating diseases critically depends on the success

112 te ratio, 0.90 [95% CI, 0.70-1.15]) or other demyelinating diseases (crude incidence rates, 7.54 even

113 In multiple sclerosis, an inflammatory demyelinating disease, endogenous remyelination does occ

114 ng SHP-1 (me/me) display severe inflammatory demyelinating disease following inoculation with the The

115 ) from SJL/J mice, susceptible to autoimmune demyelinating disease following Theiler's virus (TMEV) i

116 nterleukin-6 (IL-6) levels contribute to the demyelinating disease found in chronically infected SJL/

117 In the 2.3% with demyelinating disease, gabapentin was the most likely se

118 MHV CNS infection and developed progressive demyelinating disease, germline IgM produced in activati

119 Theiler's virus-induced demyelinating disease has been extensively investigated

120 hocytes in the pathophysiology of autoimmune demyelinating disease has led to a renewed interest in B

121 ed that myelitis occurring in the idiopathic demyelinating diseases (i.e., multiple sclerosis versus

122 ients with biopsy confirmed CNS inflammatory demyelinating disease (IDD).

123 spectrum disorders (NMOSD) are inflammatory demyelinating diseases (IDD) with a specific biomarker,

124 D8 T cells results in an attenuated clinical demyelinating disease in C57BL/6 mice with immunization-

125 sive multifocal leukoencephalopathy (PML), a demyelinating disease in humans.

126 that has been linked to JME, an inflammatory demyelinating disease in Japanese macaques that mimics m

127 As such, TMEV-induced demyelinating disease in mice provides a highly relevant

128 epitopes is critical for the development of demyelinating disease in SJL mice.

129 yelitis virus (TMEV)-induced immune-mediated demyelinating disease in susceptible mouse strains has b

130 itis virus (TMEV) induces an immune-mediated demyelinating disease in susceptible mouse strains such

131 yelitis virus (TMEV) induces immune-mediated demyelinating disease in susceptible SJL/J mice but not

132 yelin can be replaced after injury or during demyelinating diseases in a regenerative process called

133 is result in the impairment of recovery from demyelinating diseases in the adult.

134 cells against VP3(159-166), did not develop demyelinating disease, in contrast to wild-type virus or

135 dence ratio, 1.05 [95% CI, 0.79-1.38]; other demyelinating diseases: incidence ratio, 1.14 [95% CI, 0

136 risk factor for central nervous system (CNS) demyelinating diseases including multiple sclerosis (MS)

137 ar endothelium is a key step in inflammatory demyelinating diseases including multiple sclerosis (MS)

138 in the development of central nervous system demyelinating diseases, including multiple sclerosis, re

139 cations of resveratrol in human inflammatory demyelinating diseases, including multiple sclerosis.

140 on with these epitopes on the development of demyelinating disease indicated that capsid-specific CD4

141 urine encephalomyelitis virus (TMEV)-induced demyelinating disease is a relevant mouse model for the

142 ibronectin and vitronectin deposition during demyelinating disease is an important influence on micro

143 Progression of demyelinating diseases is caused by an imbalance of two

144 genesis of multiple sclerosis (MS) and other demyelinating diseases is controversial, in part because

145 Multiple sclerosis (MS), an inflammatory demyelinating disease, is a major cause of neurological

146 patient who died from a rapidly progressing demyelinating disease known as progressive multifocal le

147 failure is a major goal of new therapies for demyelinating diseases like multiple sclerosis.

148 ant factor in determining disease outcome in demyelinating diseases like multiple sclerosis.

149 SIRT1 reduces neuronal loss in this chronic demyelinating disease model and that this is associated

150 urine encephalomyelitis virus (TMEV)-induced demyelinating disease model of multiple sclerosis that C

151 differentiation and induce remyelination in demyelinating disease models.

152 in the pathogenesis of the human autoimmune demyelinating disease multiple sclerosis (MS) and in its

153 The demyelinating disease multiple sclerosis (MS) has an ear

154 Current therapies for the autoimmune demyelinating disease multiple sclerosis (MS) target inf

155 In the human CNS demyelinating disease multiple sclerosis (MS), remyelina

156 PCs), thereby impeding remyelination, in the demyelinating disease multiple sclerosis (MS).

157 functional impairment that characterizes the demyelinating disease multiple sclerosis (MS).

158 utes to the pathogenesis of the inflammatory demyelinating disease multiple sclerosis (MS).

159 act role(s) of the cytokine IFN-gamma in the demyelinating disease multiple sclerosis remain controve

160 of permanent disability in the inflammatory demyelinating disease multiple sclerosis, but no therapi

161 cephalomyelitis, a rodent model of the human demyelinating disease multiple sclerosis.

162 ) is a widely used animal model of the human demyelinating disease multiple sclerosis.

163 gical disability in individuals with the CNS demyelinating disease multiple sclerosis.

164 In the most prominent demyelinating disease, multiple sclerosis, the regenerat

165 yelination similar in pathology to the human demyelinating disease, multiple sclerosis.

166 spinal cord injury, peripheral nerve injury, demyelinating disease, neuromuscular disorders, and seiz

167 The neuroinflammatory demyelinating disease neuromyelitis optica is marked by

168 autoantibody found in the neuroinflammatory demyelinating disease neuromyelitis optica.

169 euromyelitis optica (NMO) is an inflammatory demyelinating disease of spinal cord and optic nerve cau

170 ifocal leukoencephalopathy (PML) is a severe demyelinating disease of the brain caused by JC virus (J

171 sive multifocal leukoencephalopathy (PML), a demyelinating disease of the brain caused by the polyoma

172 Multiple sclerosis (MS) is an inflammatory, demyelinating disease of the central nervous system (CNS

173 ple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS

174 Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS

175 Multiple sclerosis is an inflammatory demyelinating disease of the central nervous system (CNS

176 Multiple sclerosis is an inflammatory, demyelinating disease of the central nervous system (CNS

177 NMOSD is a recently defined demyelinating disease of the central nervous system (CNS

178 ple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS

179 euromyelitis optica (NMO) is an inflammatory demyelinating disease of the central nervous system asso

180 Neuromyelitis optica is an inflammatory demyelinating disease of the central nervous system asso

181 euromyelitis optica (NMO) is an inflammatory demyelinating disease of the central nervous system caus

182 euromyelitis optica (NMO) is an inflammatory demyelinating disease of the central nervous system caus

183 euromyelitis optica (NMO) is an inflammatory demyelinating disease of the central nervous system in w

184 Multiple sclerosis (MS) is a common demyelinating disease of the central nervous system medi

185 omyelitis optica, an idiopathic inflammatory demyelinating disease of the central nervous system pred

186 tifocal leukoencephalopathy (PML) is a fatal demyelinating disease of the central nervous system resu

187 Multiple sclerosis (MS) is a demyelinating disease of the central nervous system that

188 ve multifocal leukoencephalopathy (PML) is a demyelinating disease of the central nervous system that

189 s Devic's disease) is an idiopathic, severe, demyelinating disease of the central nervous system that

190 Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system trad

191 Multiple sclerosis is an inflammatory demyelinating disease of the central nervous system with

192 h multiple sclerosis, a chronic inflammatory demyelinating disease of the central nervous system with

193 Multiple sclerosis (MS) is a demyelinating disease of the central nervous system, lea

194 onsidered the prototype for an inflammatory, demyelinating disease of the central nervous system, mod

195 autoimmune, inflammatory, neurodegenerative, demyelinating disease of the central nervous system, pre

196 euromyelitis optica (NMO) is an inflammatory demyelinating disease of the central nervous system.

197 leukoencephalopathy (PML) is an often-fatal demyelinating disease of the central nervous system.

198 Multiple sclerosis is a chronic inflammatory demyelinating disease of the central nervous system.

199 ple sclerosis (MS) is the major inflammatory demyelinating disease of the central nervous system.

200 expression of viral proteins, and induces a demyelinating disease of the central nervous system.

201 sclerosis (MS) (n=43,879), an inflammatory, demyelinating disease of the central nervous system.

202 Centres managing patients with demyelinating disease of the CNS across Australia and Ne

203 euromyelitis optica (NMO) is an inflammatory demyelinating disease of the CNS and affects women of ch

204 Multiple sclerosis (MS) is an inflammatory demyelinating disease of the CNS and remyelination in MS

205 Multiple sclerosis (MS) is a demyelinating disease of the CNS characterized by inflam

206 lls, and its role in autoimmune inflammatory demyelinating disease of the CNS has not been studied.

207 Multiple sclerosis (MS) is an inflammatory, demyelinating disease of the CNS mediated by self-reacti

208 Multiple sclerosis is an inflammatory, demyelinating disease of the CNS of presumed autoimmune

209 tiple sclerosis (MS), a chronic inflammatory demyelinating disease of the CNS of presumed autoimmune

210 Multiple sclerosis (MS) is an autoimmune demyelinating disease of the CNS resulting from a progre

211 sclerosis (MS) is an autoimmune inflammatory demyelinating disease of the CNS that causes disability

212 ultiple sclerosis (MS) is an immune-mediated demyelinating disease of the CNS that has been linked wi

213 AE) is a CD4(+) T cell-mediated inflammatory demyelinating disease of the CNS that serves as a model

214 mmune encephalomyelitis is a T cell-mediated demyelinating disease of the CNS that serves as a model

215 ultiple sclerosis (MS) is an immune-mediated demyelinating disease of the CNS, and CD8 T cells are th

216 Multiple sclerosis is a sexually dimorphic, demyelinating disease of the CNS, and experimental aller

217 Multiple sclerosis (MS) is an inflammatory demyelinating disease of the CNS.

218 Multiple sclerosis (MS) is an inflammatory demyelinating disease of the CNS.

219 tiple sclerosis (MS) is a neuroinflammatory, demyelinating disease of the CNS.

220 e sclerosis (MS), a chronic inflammatory and demyelinating disease of the CNS.

221 of multiple sclerosis (MS), an inflammatory demyelinating disease of the CNS.

222 T Multiple sclerosis (MS) is an inflammatory demyelinating disease of the CNS.

223 ultiple Sclerosis (MS) is an immune-mediated demyelinating disease of the human central nervous syste

224 Multiple Sclerosis (MS) is an inflammatory demyelinating disease of the human central nervous syste

225 e sclerosis (MS) is an inflammatory-mediated demyelinating disease of the human central nervous syste

226 MS) is a spontaneous, acquired, inflammatory demyelinating disease of the human CNS.

227 tifocal leukoencephalopathy (PML) is a fatal demyelinating disease of the white matter affecting immu

228 ve multifocal leukoencephalopathy (PML) is a demyelinating disease of the white matter of the human b

229 m the traditional view of a T cell-mediated, demyelinating disease of the white matter to include a b

230 terogeneous group of idiopathic inflammatory demyelinating diseases of the central nervous system is

231 ise for more precise diagnosis of idiopathic demyelinating diseases of the central nervous system.

232 w diagnostic markers in these two autoimmune demyelinating diseases of the central nervous system.

233 ne encephalomyelitis (EAE), are inflammatory demyelinating diseases of the CNS that are suppressed by

234 re a promising approach for the treatment of demyelinating diseases of the CNS.

235 therapeutic modulation of ERK1/2 activity in demyelinating disease or peripheral neuropathies must be

236 trated to be important in the development of demyelinating disease presumably by attracting inflammat

237 We propose that the inflammatory demyelinating disease process in early multiple sclerosi

238 virus (JCPyV) causes the rapidly progressing demyelinating disease progressive multifocal leukoenceph

239 mavirus and the causative agent of the fatal demyelinating disease progressive multifocal leukoenceph

240 tion and is the causative agent of the fatal demyelinating disease progressive multifocal leukoenceph

241 ty of the population and can cause the fatal demyelinating disease progressive multifocal leukoenceph

242 compromised individuals results in the fatal demyelinating disease progressive multifocal leukoenceph

243 ression, JCV can infect the brain, causing a demyelinating disease, progressive multifocal leukoencep

244 tral nervous system and chronic inflammatory demyelinating disease, providing an experimental animal

245 finding may have important implications for demyelinating diseases, psychiatric disorders, and cogni

246 DA-induced demyelinating disease serves as a model of human multipl

247 urine encephalomyelitis virus (TMEV)-induced demyelinating disease serves as a relevant mouse model f

248 composition and low MBP concentration, as in demyelinating disease, show structural instabilities and

249 ising strategies to advance the treatment of demyelinating diseases.SIGNIFICANCE STATEMENT The benefi

250 ystem (CNS) causes an immune system-mediated demyelinating disease similar to human multiple sclerosi

251 reported in patients that recover from acute demyelinating diseases such as Guillain-Barre syndrome.

252 ss of visual function frequently accompanies demyelinating diseases such as multiple sclerosis (MS) a

253 tions including central nervous system (CNS) demyelinating diseases such as multiple sclerosis (MS) a

254 erapy in the CNS, particularly for long-term demyelinating diseases such as multiple sclerosis (MS).

255 elin regeneration can occur spontaneously in demyelinating diseases such as multiple sclerosis (MS).

256 therapeutic approaches for the treatment of demyelinating diseases such as multiple sclerosis (MS).S

257 ul in many neurological disorders, including demyelinating diseases such as multiple sclerosis and th

258 Demyelinating diseases such as multiple sclerosis are ch

259 nstitute clinically debilitating sequelae in demyelinating diseases such as multiple sclerosis, but t

260 axons, associated with traumatic injury and demyelinating diseases such as multiple sclerosis, cause

261 In demyelinating diseases such as multiple sclerosis, disru

262 Previously of interest in demyelinating diseases such as multiple sclerosis, myeli

263 lopment and crucial for myelin repair in CNS demyelinating diseases such as multiple sclerosis.

264 emyelination biology and its presentation in demyelinating diseases such as multiple sclerosis.

265 ical targets for therapeutic intervention in demyelinating diseases such as multiple sclerosis.

266 o ameliorate the devastating consequences of demyelinating diseases such as multiple sclerosis.

267 ng rates underlies degenerative processes in demyelinating diseases such as multiple sclerosis.

268 approach for potential treatment of chronic demyelinating diseases such as multiple sclerosis.

269 s can be therapeutically enhanced in chronic demyelinating diseases such as multiple sclerosis.

270 loping new therapeutic tools to intervene in demyelinating diseases such as multiple sclerosis.

271 hat Shp2 is a relevant therapeutic target in demyelinating diseases such as multiple sclerosis.SIGNIF

272 target of axonal protection in inflammatory demyelinating diseases, such as multiple sclerosis and p

273 Demyelinating diseases, such as multiple sclerosis, are

274 Demyelinating diseases, such as multiple sclerosis, are

275 BP is an abundant myelin protein involved in demyelinating diseases, such as multiple sclerosis.

276 gene expression and induces an inflammatory demyelinating disease that is thought to be immune media

277 ssive multifocal leukoencephalopathy, a rare demyelinating disease that occurs in the setting of prol

278 autoimmune encephalomyelitis, an autoimmune demyelinating disease that resembles multiple sclerosis.

279 are, typically fatal, central nervous system demyelinating disease that results from reactivation of

280 Because, in demyelinating diseases, the myelin formed during remyeli

281 ically useful as immunomodulatory agents for demyelinating diseases through a novel mechanism involvi

282 Although TMEV-induced demyelinating disease (TMEV-IDD) is thought to be immune

283 ler's murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD), a well-established ani

284 ler's murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD).

285 the pathogenesis of Theiler's virus-induced demyelinating disease (TMEV-IDD).

286 nying immune responses in the development of demyelinating disease, transgenic mice expressing the P1

287 ve multifocal leukoencephalopathy (PML) is a demyelinating disease triggered by infection with the hu

288 iple sclerosis cases and 3300 cases of other demyelinating diseases were identified, of which 73 and

289 peutic enhancement of remyelination in those demyelinating diseases where GPR17 is highly expressed,

290 sceptible mice results in an immune-mediated demyelinating disease which is considered a relevant vir

291 e innate immune response developed a reduced demyelinating disease which was associated with a decrea

292 with TMEV induces the development of chronic demyelinating disease, which is considered a relevant in

293 specific CD4(+) T cell responses and reduced demyelinating disease, which was associated with decreas

294 onfirmed central nervous system inflammatory demyelinating disease who had undergone either diagnosti

295 s virus (JHMV) results in an immune-mediated demyelinating disease with clinical and histologic simil

296 TMEV-infected mice develop a demyelinating disease with clinical symptoms beginning a

297 Multiple sclerosis (MS) is a multifocal demyelinating disease with progressive neurodegeneration

298 e sclerosis (MS) are considered inflammatory demyelinating diseases with distinguishing pathological

299 titis virus (JHMV) develop acute and chronic demyelinating diseases with histopathological similariti

300 mmune cell infiltration in neuroinflammatory demyelinating diseases; yet, the causal link between inf